Researchers Unveil a New Theory Explaining Long-term Pain Relief
Stimulation of peripheral nerves warrants consideration early in the care continuum
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) A novel theory recently published in the
Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve stimulation (PNS) may recondition the central nervous system (CNS) to restore normal pain processing and provide long-term pain relief for patients. This short-term treatment may replace the need for permanently implanted systems in many patients.
Chronic pain may occur due to an imbalance in nerve signal processing within the CNS as a result of reduced healthy inputs coming from within the region of pain. The new theory proposes that increasing healthy neural inputs by stimulating peripheral nerves can recondition the CNS and restore healthy pain processing. Pain relief following a 60-day peripheral nerve stimulation treatment has been repo
Product News: Abbott introduces NeuroSphere™ Virtual Clinic, first-of-its-kind remote neuromodulation patient-care technology in the U.S.
Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location
10 Mar 2021
Abbott today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering from chronic pain or movement disorders who don’t live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19.
Abbott Announces U.S. Launch Of NeuroSphere Virtual Clinic
NORTH CHICAGO (dpa-AFX) - Abbott (ABT) Monday announced the launch of NeuroSphere Virtual Clinic, a technology that allows patients to communicate with physicians and receive treatment remotely.
The virtual clinic was approved by the FDA. It will be helpful for patients suffering from chronic pain or movement disorders who don t live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19.
Abbott s NeuroSphere Virtual Clinic connects with a doctor via secure in-app video chat and an integrated remote programming feature.
Abbott Introduces NeuroSphere Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
Abbott today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering …
Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering from chronic pain or mo